GLUE · Monte Rosa Therapeutics, Inc.
$15.50
-0.34 (-2.15%)
At close · Aug 14
Market Cap
$1.32B
Shares
85.31M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$123.67M
+63.5%
FY2025
Net Income
-$38.6M
+46.9%
FY2025
Operating Margin
-43.83%
+63.4pp
FY2025
Operating Cash Flow
-$22.8M
-154.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $28.73M | $123.67M | $75.62M | $0 | — | — | — | |
| $170.69M | $141.5M | $121.56M | $111.27M | $85.06M | $57.16M | $24.01M | |
| $39.89M | $36.38M | $35.17M | $32.04M | $27.32M | $15.73M | $4.01M | |
| $2.66M | $2.5M | $2.1M | $2.1M | $2.5M | — | — | |
| $210.58M | $177.88M | $156.73M | $143.31M | $112.38M | $72.88M | $28.01M | |
| -$181.85M | -$54.21M | -$81.11M | -$143.31M | -$112.38M | -$72.88M | -$28.01M | |
| — | -43.83% | -107.26% | — | — | — | — | |
| $17.88M | $14.49M | $10.98M | $8.3M | $3.88M | -$1.08M | -$7.87M | |
| -$163.97M | -$39.72M | -$70.13M | -$135.01M | -$108.5M | — | — | |
| -$2.86M | -$1.1M | $2.57M | $338K | $0 | — | — | |
| -$161.09M | -$38.6M | -$72.7M | -$135.35M | -$108.5M | -$73.96M | -$35.88M | |
| — | -31.21% | -96.14% | — | — | — | — | |
| -$162.91M | -$39.1M | -$73.33M | -$136.32M | -$108.23M | -$74.92M | -$36.94M | |
| shares | — | 83.07M | 73.91M | 51.4M | 47.23M | 25M | 1.52M |
| shares | — | 83.07M | 73.91M | 51.4M | 47.23M | 25M | 1.52M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2025: $0 in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.26×
EV/EBIT
—
Peer median 25.83×
P/E (TTM)
—
Peer median 16.89×
Peer medians compare against the 296 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
1826457
CUSIP
61225M102
13F (30d)
188 filings
184 filers
Visit website
Investor relations